Renal Cell Carcinoma Treatment Regimens
Access a treatment regimen chart with detailed information for renal cell carcinoma, including tyrosine kinase inhibitors and cytokine therapy.
Access a treatment regimen chart with detailed information for renal cell carcinoma, including tyrosine kinase inhibitors and cytokine therapy.
If crowdfunding doesn’t work, here’s how oncologists can help patients with financial toxicity.
Following nephrectomy for renal cell carcinoma with lymph node involvement, patients have a 5-year survival rate of only 28%, a new study found.
Superiority of the regimen was shown in intermediate- and poor-risk groups, as well as in intention-to-treat populations.
Conditional survival may more accurately assess prognosis than traditional survival for patients with metastatic kidney cancer, but the metric is not without its caveats.
Among patients with pT1b renal cell carcinoma, cryoablation is associated with a 2.5-fold higher 5-year cancer-specific mortality rate compared with partial nephrectomy, a study found.
Biosimilars Mvasi and Kanjinti are now available in the United States.
Cytoreductive nephrectomy (CN) by itself for metastatic renal cell carcinoma is associated with a 43% decreased risk of death compared with CN plus targeted therapy.
In a meta-analysis, partial and radical nephrectomy were associated with similar long-term overall survival, but cancer-specific survival was better with radical nephrectomy.
Prospective validation shows decrease in predictive ability compared with previous retrospective validations.